Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MD-7246
- Development stage
- Discontinued
- Lead developer
- Ironwood Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MD-7246 is a delayed-release formulation of linaclotide designed to target the ileocaecal junction and caecum with the aim of relieving abdominal pain independently of bowel function. It was developed as an oral, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D)[1][3][7]. The formulation was specifically designed to provide targeted delivery of linaclotide to the colon, where the majority of the abdominal pain associated with IBS is believed to originate, and to limit fluid secretion in the small intestine resulting in minimal impact on bowel function[1][7].
- Other names
- DR2DR-2DR 2
02
Targets
GUCY2C (Guanylate cyclase C receptor)
Beyond the preview
Go deeper on MD-7246.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MD-7246.